Why Private VC Leaves Gaps
Government venture capital is meant to alter a private financing system, so this chapter focuses on how that system makes investment decisions and why it can leave some ventures without suitable capital. The useful outcome is not a list of market failures. It is the ability to trace a company from uncertainty to screening, staged funding, and exit, then identify which specific friction a public programme is claiming to address.
Equity is a way to finance uncertainty
A young company with an untested product is a poor fit for the ordinary loan. A lender expects scheduled interest and principal payments, which in turn require a reasonably predictable business model and cash flow. An innovative venture may need to spend years developing a product before it knows who will buy it. It may have valuable technical knowledge but no revenue, assets that can easily secure debt, or evidence that its market will form at all. The problem is not necessarily that the idea has no value. It is that debt asks for a kind of certainty the venture cannot yet provide.
Venture capital changes the claim on the company. Instead of receiving fixed payments, the investor takes an equity-linked position—usually a minority ownership stake—and shares in the upside if the company grows. If the company fails, the investor can lose much or all of the investment. If it succeeds, the return comes from the eventual value of the stake, often through a sale or another exit. The return is therefore tied to the distribution of outcomes across a portfolio, not to a predictable interest stream from every individual company.
That structure requires more than a transfer of money. In the limited-partnership model described by the OECD, limited partners supply capital to a fund, while general partners manage it. LPs may be pension funds, insurance companies, banks, endowments, family offices, or private individuals. They normally do not choose each start-up. GPs, who receive management fees and a share of profits through carried interest, formulate the investment strategy, select opportunities, negotiate terms, and oversee the portfolio. The separation gives the decision-makers a specialised role, but it also means that the people who own the capital and the people who deploy it do not have identical information or control.
The GP's first task is screening. A promising pitch is not yet an investable company, so the manager examines the team, technology, market, competitive position, financing need, and likely route to growth. Equity ownership gives the investor information and monitoring rights that a lender may not have. The investor can negotiate control rights, take a board role, recruit managers, introduce customers or partners, and help the company raise its next round. These activities are part of the value proposition of VC: the fund is an intermediary that processes information and connects a young company to resources it cannot yet organise by itself.
The second important feature is staged finance. A fund does not have to release its entire commitment on day one. It can provide an initial amount, observe the results of experiments, and make a continuation decision when new information arrives. If a prototype works, customers respond, or a technical obstacle is resolved, follow-on funding becomes more defensible. If the evidence weakens the case, the manager can stop investing and limit the loss. This option is valuable precisely because innovation is uncertain: the investor is buying the right to learn before committing more capital.
Staging also creates pressure. A closed-end VC fund typically has a life of about seven to twelve years. Within that period, the GP must deploy capital, help companies develop, and sell the holdings or otherwise return proceeds to LPs. An opportunity that needs a long period merely to produce a reliable signal may be difficult to finance, even if the eventual product could be important. The private investor is not simply asking whether a technology might work. They are asking whether the available evidence will improve quickly enough, and whether the company can reach a valuable exit within the fund's operating horizon.
A signal is useful to a fund when it changes a decision, not merely when it records that work has happened. A customer trial, a working prototype, or a successful technical test can justify releasing more capital if it reduces an important uncertainty. But the same amount of effort may tell an investor less when the underlying system is expensive to build or when market adoption depends on infrastructure that does not yet exist. This creates a financing asymmetry between ventures whose learning can be demonstrated cheaply and ventures whose learning is slow, costly, or difficult to communicate to an outside investor.
Consider two early-stage companies with ambitious technologies. One can put an early version in users' hands, measure responses, and revise the product within months. The other must build a specialised prototype before a meaningful test is possible, and the test may still leave questions about regulation, manufacturing, or deployment. The first company can pass through several funding decisions while the fund still has time to act. The second may consume much of that time before its evidence becomes legible. A private screen that favours the first is not necessarily confusing technical promise with commercial promise; it may be pricing the cost and timing of information. The public-policy issue is whether the second company's longer learning cycle reflects a correctable financing gap or simply a weak opportunity.
The separation between LPs and GPs adds another layer. LPs bear the economic exposure to the fund, while GPs exercise the specialised discretion to select and support companies. Contracts, carried interest, monitoring rights, and the fund's deadline are meant to align those roles, but they cannot make uncertainty disappear. A public programme that inserts itself into this arrangement may change the resources available to the GP, the acceptable holding period, or the consequences of a failed experiment. It may improve the information process by funding work that private investors cannot yet justify. It may also weaken discipline if it makes continuation politically or financially easier without producing better evidence. The design question begins here: which part of the private decision process needs changing, and what new risk does that change introduce?
The sequence explains why changing screening is such a consequential public-policy choice. A government fund can supply money, but it may also change who interprets the evidence, which signals matter, how long the company has to produce them, and whose networks are available after the investment. It can preserve the private model's discipline or deliberately relax part of it to pursue a different objective. Either choice has consequences.
Why a functioning VC market still leaves gaps
The first gap is geographic. Venture capital tends to concentrate where other parts of an innovation ecosystem are already present: universities, skilled employees, incubators, corporate partners, experienced founders, and investors. Each makes the others more useful. A manager is more likely to locate near portfolio companies; entrepreneurs are more likely to seek advice and capital where investors already have networks; successful exits attract more people and money. This cumulative process can leave a region with capable researchers or entrepreneurs but too little local deal flow and too few investors willing to learn its opportunities.
Distance is not the only problem. A thin local market may make the first investment harder to evaluate and the eventual exit harder to arrange. A company outside an established hub may lack introductions to follow-on investors, specialist directors, or potential acquirers. In that setting, a public fund might be trying to seed a market: not to declare every local company attractive, but to create enough activity, experience, and relationships for a more dynamic segment to form. The mechanism is ecosystem-building, not simply redistribution from one postcode to another.
The second gap concerns financial-market depth. VC funds rely on outside LPs, and those LPs are more plentiful where institutions can mobilise and trust capital. The OECD reports that, in the 2019–2022 period it examines, countries with lower financial-institution depth tended to have a larger government share of newly raised VC funds, while their VC markets were smaller relative to GDP. That pattern is consistent with governments stepping into a weak funding channel. It does not show that government funding caused the weakness, or that a public fund will repair it. Regulation and institutional design can sometimes expand private supply more directly—for example, by changing which institutions may invest—but those levers depend on the surrounding pension, banking, and legal systems.
Liquidity can disappear even in a deep market. VC investment moves in cycles with the economy, investor sentiment, and the availability of capital. During the COVID-19 pandemic, the OECD notes that limited partners appear to have pressured fund managers to conserve capital, contributing to reluctance to invest. Deal volumes, capital invested, and deal sizes fell, particularly for early-stage companies. A temporary matching fund or stabilisation facility may be justified in such a moment because a viable company can fail for lack of financing continuity rather than because its underlying opportunity has suddenly become worse. But emergency support and a permanent public market-making institution answer different questions and should not be evaluated by the same counterfactual.
The third gap is produced by the cost of experimentation. Innovation begins with uncertainty about whether an idea can become a useful product and a viable business. Entrepreneurs reduce that uncertainty through simulation, prototyping, mass screening, A/B testing, and other experiments. Those experiments produce information, but they also consume money and time. When the cost is low, an investor can fund several attempts, stop weak projects early, and identify promising signals before the fund's deadline. When the cost is high, the same learning process requires a larger initial commitment and a longer wait.
This difference helps explain why venture capital has been strongly concentrated in information technology. Cloud infrastructure and higher-level programming tools reduced the cost of running many digital experiments, making it easier to test, discard, and refine ideas. By contrast, new materials, carbon-sequestration methods, e-fuels, and other complex technologies may require expensive prototypes and may not offer a marketable intermediate result. A private fund that must show progress and realise exits in seven to twelve years can rationally prefer the first type of opportunity. That preference is not proof of irrational bias. It is a response to the way uncertainty, cost, and time interact with the fund contract.
A public programme may therefore be designed to absorb more of the early uncertainty or to remain invested longer. It can target a technology where private investors would otherwise wait for someone else to finance the costly experiment. Yet this is not a free correction. Public managers still need a way to distinguish an expensive but informative experiment from a project whose prospects are simply weak. Patient capital can extend the runway; it cannot remove technical risk.
A fourth gap arises when private returns do not capture social returns. New knowledge may spill over to other firms, researchers, or industries. The originating investor may not be able to appropriate the full benefit, especially where intellectual-property rights are difficult to define or where rapid diffusion is socially desirable. A technology can also have effects on health, the environment, regional opportunity, or inclusion that matter to society but do not appear in the private investor's expected cash flow. Government can take those benefits into account, but doing so changes the meaning of a “good” investment. A project with a modest financial return may be defensible under a social mandate; it may be a poor choice for a fund whose only objective is commercial return.
The same logic applies to people who are underrepresented in high-growth entrepreneurship and VC. If funding networks draw heavily on existing relationships and familiar signals, capable founders or ideas may be missed. Targeted public capital can broaden access, but the mere presence of a target group does not establish that the programme found the best way to improve innovation or inclusion. A credible assessment would need to examine who gained access, what happened to the companies, and what would have occurred without the intervention.
These gaps should not be collapsed into one general claim that “the market fails.” A regional shortage calls attention to networks and local investor capability. A shallow financial market points toward the supply of LP capital and institutional rules. A crisis liquidity shock may call for temporary continuity. An expensive, long experiment points toward patient staged funding. Knowledge spillovers and underrepresentation justify considering objectives beyond private return. The diagnosis determines what a public fund must change, and it also determines what success should mean.
That distinction is the foundation for judging government venture capital. If the public programme merely finances a company that a private fund was ready to back on the same terms, it may be transferring risk without adding investment. If it reaches a genuinely underfunded opportunity, improves the information available to later investors, and helps build a durable network, it may be additional. The evidence supplied here supports those as competing mechanisms, not as a universal verdict. The next question is how a government turns a diagnosis into a programme whose objectives, ownership, and financial terms give private actors a reason to respond differently.